Who are CIC Vaccine with Matrix-M Adjuvant's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Comirnaty, Prevnar 20, sIPV+DTaP+MMR, Vaqta Injectable Product, Mpox Vaccine, engineered HB vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cic-vaccine-with-matrix-m-adjuvant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

CIC Vaccine with Matrix-M Adjuvant — Competitive Intelligence Brief

CIC Vaccine with Matrix-M Adjuvant (CIC Vaccine with Matrix-M Adjuvant) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Immunology.

phase 2 vaccine Immunology Small molecule Live · refreshed every 30 min

Target snapshot

CIC Vaccine with Matrix-M Adjuvant (CIC Vaccine with Matrix-M Adjuvant) — Novavax. The CIC vaccine with Matrix-M adjuvant works by stimulating the body's immune system to produce a protective response against the COVID-19 virus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CIC Vaccine with Matrix-M Adjuvant TARGET	CIC Vaccine with Matrix-M Adjuvant	Novavax	phase 2	vaccine
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
sIPV+DTaP+MMR	sIPV+DTaP+MMR	China National Biotec Group Company Limited	marketed	Combination vaccine
Vaqta Injectable Product	Vaqta Injectable Product	National Taiwan University Hospital	marketed	Inactivated viral vaccine	Hepatitis A virus surface antigen
Mpox Vaccine	Mpox Vaccine	Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia	marketed	vaccine
engineered HB vaccine	engineered HB vaccine	Southeast University, China	marketed	Vaccine	Hepatitis B surface antigen (HBsAg)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (vaccine class)

Pfizer · 20 drugs in this class
Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
GlaxoSmithKline · 12 drugs in this class
Merck Sharp & Dohme LLC · 12 drugs in this class
Centers for Disease Control and Prevention · 9 drugs in this class
Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
Beijing Center for Disease Control and Prevention · 6 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
Sinovac Biotech Co., Ltd · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CIC Vaccine with Matrix-M Adjuvant — Competitive Intelligence Brief. https://druglandscape.com/ci/cic-vaccine-with-matrix-m-adjuvant. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab